Neurogen Corporation Announces Second Quarter 2008 Financial Results

Neurogen Corporation (Nasdaq: NRGN), a drug development company focused on improved drugs for psychiatric and neurological disorders, today announced financial results for the three and six month periods ended June 30, 2008. During the second quarter, the Company recognized certain non-recurring charges and gains related to previously announced restructurings and the Company’s April 2008 private equity financing, which affected net loss for the three and six month periods ended June 30, 2008 and are discussed further below. On a Generally Accepted Accounting Principles in the United States ("GAAP”) basis, including non-recurring matters, Neurogen recognized a net loss for the second quarter of 2008 of $6.4 million and a net loss attributable to common stockholders of $11.8 million, or $0.28 per share on 42.1 million weighted average shares outstanding. On a non-GAAP basis, excluding non-recurring matters, net loss for the quarter totaled $8.5 million, or $0.20 per share. This compares to a net loss during the second quarter of 2007 of $13.6 million, or $0.33 per share on 41.8 million weighted average shares outstanding. On a GAAP basis, including non-recurring matters, the Company recognized a net loss for the six months ended June 30, 2008 of $23.0 million and a net loss attributable to common stockholders of $28.4 million, or $0.67 per share on 42.1 million weighted average shares outstanding. On a non-GAAP basis, excluding non-recurring matters, net loss for the period totaled $22.6 million, or $0.54 per share. This compares to a net loss of $32.9 million, or $0.79 per share on 41.8 million weighted average shares outstanding for the six month period ended June 30, 2007. Neurogen’s total cash and marketable securities as of June 30, 2008 totaled $42.8 million, which included $28.4 million in net proceeds received in April for the private placement offering of exchangeable preferred stock and warrants with certain institutional investors. "We remain focused on our ongoing Phase 2 clinical trials in Parkinson’s disease and restless legs syndrome with aplindore, our dopamine D2 partial agonist,” said Stephen R. Davis, President and CEO. "We expect to have results from these studies by the end of the year. We also continue to carefully limit our resource commitments while we gather and evaluate data related to adipiplon, our GABA alpha 3 partial agonist. With $42.8 million as of the end of the quarter, we have the capital to get to important clinical results and then determine how best to employ our capital for our shareholders’ benefit,” Mr. Davis added. Research and development expenses for the second quarter of 2008 decreased to $8.0 million from $16.4 million in the second quarter of 2007 and for the six month period of 2008, decreased to $20.0 million from $35.3 million in the comparable period of 2007. The decrease in R&D expenses for the quarter was due primarily to decreases in non-cash compensation from stock option expense, salaries, benefits and lower spending in Neurogen’s clinical and preclinical drug development programs. General and administrative expenses for the second quarter of 2008 decreased to $0.8 million, compared to $3.5 million for the same period in 2007, and for the six month period of 2008, decreased to $2.9 million from $7.2 million for the comparable period of 2007. The decrease for the quarter was due mainly to decreases in non-cash compensation from stock option expense, salaries, benefits, legal and patent expenses. Neurogen had no operating revenue for the second quarter of 2008, compared to $5.5 million for the second quarter of 2007, and no operating revenue for the six month period of 2008, compared to $7.9 million for the comparable period of 2007. The decrease in operating revenue for the quarter was due to the previously announced conclusion of the research component of Neurogen’s VR1 collaboration with Merck. This collaboration is now focused on the development of candidates previously discovered in the companies’ joint research program. Non-recurring matters Neurogen recognized restructuring charges of $2.6 million in the second quarter of 2008 and $5.1 million for the six month period ended June 30, 2008. These charges are associated with reductions in force announced on February 5, 2008 and April 9, 2008. In the second quarter of 2008, Neurogen also took a non-cash asset impairment charge of $7.2 million related to the value of the Company’s facilities previously used for research activities. In April 2008, Neurogen closed a private placement offering of exchangeable preferred stock and warrants with certain institutional investors. On July 25, 2008, following approval of the Company’s stockholders, the preferred shares issued in the financing converted to common shares, and the Company’s stockholders approved the authorization of additional shares underlying the warrants. Since these shareholder approvals occurred after the end of the second quarter, GAAP required that, at June 30, 2008, the preferred stock be shown as mezzanine equity between total liabilities and stockholders’ equity and the warrants be shown as a liability on the accompanying balance sheet. In future financial statements dated subsequent to the shareholder approval date of July 25, 2008, the warrants will not be deemed to be a liability and the stock, reflecting the exchange, will be presented as common shares rather than preferred. In connection with the securities issued in the April financing and in accordance with the required GAAP treatment of these instruments prior to stockholder approval, in the second quarter of 2008 Neurogen recognized a non-cash charge of approximately $5.4 million related to the preferred stock and a non-cash gain of approximately $12 million related to the warrants. The $5.4 million non-cash charge reflected the calculation of contingent preferred dividends, accretion of the preferred stock to redemption value and the amortization of discount associated with the preferred stock. Pursuant to GAAP, these items are considered deemed preferred dividends and were added to net loss, resulting in a net loss attributable to common stockholders of $11.8 million and $28.4 million for the three and six month periods ended June 30, 2008. The $12 million non-cash gain recorded in the second quarter related to a decrease in the liability associated with the ascribed value of the warrants as a result of a decrease in the Company’s stock price from date of issuance on April 7, 2008 through June 30, 2008. Upon shareholder approval of the authorization of common shares underlying the warrants on July 25, 2008, this deemed liability was satisfied. Webcast The Company will host a conference call and webcast to discuss second quarter results at 8:30 a.m. EDT today, August 7, 2008. The webcast will be available in the Investor Relations section of www.neurogen.com and will also be archived there. A replay of the call will be available after 10:30 a.m. ET today and accessible through the close of business, August 14, 2008. To replay the conference call, dial 888-286-8010, or for international callers, 617-801-6888, and use the pass code: 64223755. About Neurogen Neurogen Corporation is a drug development company focusing on small-molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including Parkinson’s disease, restless legs syndrome (RLS) insomnia, anxiety and pain. Neurogen conducts its drug development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise. Statement Regarding Adjusted (Non-GAAP) Financial Information In addition to disclosing financial results calculated in accordance with GAAP, the Company has included certain adjusted financial results. Reconciliations between GAAP and adjusted earnings for the three and six months ended June 30, 2008 and 2007 are provided in the table below. The Company believes that the presentation of adjusted results provides meaningful supplemental information regarding our financial results for the three and six months ended June 30, 2008 as compared to the three and six months ended June 30, 2007 because the adjustments between GAAP and adjusted earnings provide information related to the ongoing operations of the Company. The Company believes that this financial information is useful to management and investors in assessing our historical performance and results. The Company will use these adjusted financial measures when evaluating its financial results, as well as for internal planning and forecasting purposes. The adjusted financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. The adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Our results under GAAP have been adjusted for the following events that occurred during the three and six months ended June 30, 2008 and 2007: (1) reductions to the Company’s workforce that resulted in additional expense, (2) asset impairment charges associated with the potential sale of our buildings, (3) gain on warrants to purchase common stock associated with our 2008 private placement, and (4) deemed preferred dividends also associated with our 2008 private placement. See the table and accompanying footnotes below for a detailed reconciliation of GAAP and adjusted earnings. Reconciliations between GAAP and Non-GAAP earnings for the three and six months ended June 30, 2008 and 2007 are provided in the following table:   Three Months Ended   Three Months Ended   Six Months Ended   Six Months Ended June 30, 2008 June 30, 2007 June 30, 2008 June 30, 2007 [in thousands except per share amounts] (unaudited) Net loss attributable to common stockholders (GAAP) $ (11,841 ) $ (13,639 ) $ (28,359 ) $ (32,919 ) Charge related to the reduction in workforce 2,640 --- 5,130 --- Asset impairment charges 7,200 --- 7,200 --- Gain on warrants to purchase common stock (11,954 ) --- (11,954 ) --- Deemed preferred dividends   5,407       ---       5,407       ---   Adjusted net loss (Non- GAAP)   (8,548 )     (13,639 )     (22,576 )     (32,919 ) Basic and diluted loss per share attributable to common stockholders (GAAP) $ (0.28 )   $ (0.33 )   $ (0.67 )   $ (0.79 ) Basic and diluted loss per share (Non-GAAP) $ (0.20 )   $ (0.33 )   $ (0.54 )   $ (0.79 ) Safe Harbor Statement The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws that involve risks and uncertainties as detailed from time to time in Neurogen's SEC filings, including its most recent 10-K. Such forward-looking statements relate to events or developments that we expect or anticipate will occur in the future and include, but are not limited to, statements that are not historical facts relating to the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. Actual results may differ materially from such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of the Company's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, the Company’s ability to retain key employees, sufficiency of cash to fund the Company's planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provides no assurance that this will be true in future studies. Neurogen disclaims any intent and does not assume any obligation to update these forward-looking statements, other than as may be required under applicable law. NEUROGEN CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except per share data) (unaudited)         Three MonthsendedJune 30, 2008   Three MonthsendedJune 30, 2007   Six MonthsendedJune 30, 2008   Six MonthsendedJune 30, 2007           Operating revenues: License fees $ --- $ 3,867 $ --- $ 5,232 Research revenues   ---     1,666     ---     2,706   Total operating revenues --- 5,533 --- 7,938   Operating expenses: Research and development 7,995 16,373 20,049 35,296 General and administrative 756 3,473 2,919 7,230 Restructuring charges 2,640 --- 5,130 --- Asset impairment charges   7,200     ---     7,200     ---   Total operating expenses   18,591     19,846     35,298     42,526   Operating loss (18,591 ) (14,313 ) (35,298 ) (34,588 )   Gain on warrants to purchase common stock 11,954 --- 11,954 --- Other income, net   180     562     346     1,446   Total other income, net 12,134 562 12,300 1,446   Income tax benefit   23     112     46     223   Net loss (6,434 ) (13,639 ) (22,952 ) (32,919 ) Deemed preferred dividends   (5,407 )   ---     (5,407 )   ---   Net loss attributable to common stockholders $ (11,841 ) $ (13,639 ) $ (28,359 ) $ (32,919 )   Basic and diluted loss per share attributable to common stockholders $ (0.28 ) $ (0.33 ) $ (0.67 ) $ (0.79 )   Shares used in calculation of loss per share attributable to common stockholders: Basic and diluted   42,131     41,840     42,062     41,793   NEUROGEN CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) (unaudited)           June 30, 2008   December 31, 2007 Assets Cash and cash equivalents $ 28,935 $ 21,227 Marketable securities   13,894   21,362 Total cash and marketable securities 42,829 42,589 Receivables from corporate partners 32 188 Assets held for sale 8,379 --- Other current assets, net   3,642   3,026 Total current assets 54,882 45,803   Net property, plant and equipment 7,946 25,521 Other assets, net   38   46 Total assets $ 62,866 $ 71,370   Liabilities and Stockholders’ Equity Current liabilities Accounts payable and accrued expenses 6,986 7,787 Current portion of loans payable   5,263   5,835 Total current liabilities 12,249 13,622   Long term liabilities Loans payable, net of current portion 2,977 3,141 Warrants to purchase common stock   6,118   --- Total liabilities 21,344 16,763   Exchangeable preferred stock 15,709 ---   Total stockholders’ equity   25,813   54,607 Total liabilities and stockholders’ equity $ 62,866 $ 71,370